German site
Pharmanovia announces exclusive distribution agreement with Er-Kim for Sunosi® in Eastern Europe
PRESS RELEASE – FOR TRADE AND BUSINESS MEDIA ONLY
- This strategic partnership will enhance the availability of Sunosi® (Solriamfetol), a first-in-class treatment for Excessive Daytime Sleepiness (EDS)1, in 14 countries across the region.
Basildon, UK – 21 February 2025
Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines is pleased to announce the signing of an exclusive distribution agreement with Er-Kim, a leading pharmaceutical company with deep experience bringing novel medicines to patients in key international markets.
Under the terms of the agreement, Er-Kim will be responsible for launching and commercialising Sunosi® (Solriamfetol) in the following markets: Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia, and Slovenia. Pharmanovia will retain the marketing authorisation for the product in these territories.
“Sunosi® (Solriamfetol) represents an important advancement in the treatment of EDS, with proven clinical efficacy and a unique mechanism of action,” said Dr. James Burt, CEO, Pharmanovia. “Our primary goal is to ensure that as many patients as possible gain access to this efficacious therapy. With Er-Kim as our partner across CEE, we have identified a team with an in-depth understanding of the region and the expertise to bring innovative treatments to the CEE market.”
Cem Zorlular, CEO of Er-Kim, commented, “We are thrilled to have been selected as the exclusive launch partner for Sunosi® (Solriamfetol) in the CEE region and excited to work with Pharmanovia. This is a highly innovative treatment, and its successful introduction requires a partner with deep market knowledge and capability in navigating the regulatory, medical and commercial landscapes of these diverse markets. We are excited to work together with Pharmanovia to ensure patients in need can benefit from this important medicine.”
-Ends-
Notes to editors
For further information, please contact:
Alison Dyson, Director of Communications, Pharmanovia
07912887250/ communications@pharmanovia.com
About Pharmanovia
Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.
We do this by rediscovering, repurposing or re-engineering established medicines or by bringing to market novel medicines to improve patient outcomes and experiences.
With a diverse and growing team in over 160 countries across the globe, we deliver high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology both in rare and established diseases or conditions.
About Er-Kim
Established in 1981, Er-Kim stands at the forefront of biopharmaceutical innovation, partnering with over 40 global leaders to revolutionize patient care in key international markets, continually setting new standards in commercialization and patient access. For more information, please visit http://www.er-kim.com/.
References1